Fourth Year PhD Candidate in the Rutgers Cellular and Molecular Pharmacology PhD program, with a concentration in Cancer Biology. Working under the direction of Dr. Suzie Chen.
My current project is studying the long-term therapeutic consequences of an immune checkpoint blockade antibody, anti-PD-1 and a glutamatergic signaling inhibitor, Troriluzole in a spontaneous melanoma prone mouse model. This combination is currently under clinical investigation (NCT03229278). My study aims to develop a clinically relevant mouse model to study metastatic melanoma as well as characterize the mechanism of action of this combination. This model will allow me to identify clinically relevant prognostic biomarker(s) for treatment response. I have received the New Jersey Cancer Commission Pre-Doctoral fellowship for this project.
Fourth Year PhD Candidate in the Rutgers Cellular and Molecular Pharmacology PhD program, with a concentration in Cancer Biology. Working under the direction of Dr. Suzie Chen.
My current project is studying the long-term therapeutic consequences of an immune checkpoint blockade antibody, anti-PD-1 and a glutamatergic signaling inhibitor, Troriluzole in a spontaneous melanoma prone mouse model. This combination is currently under clinical investigation (NCT03229278). My study aims to develop a clinically relevant mouse model to study metastatic melanoma as well as characterize the mechanism of action of this combination. This model will allow me to identify clinically relevant prognostic biomarker(s) for treatment response. I have received the New Jersey Cancer Commission Pre-Doctoral fellowship for this project.